[HTML][HTML] Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non …
J Zhou, M Bao, G Gao, Y Cai, L Wu, L Lei, J Zhao, X Ji… - BMC medicine, 2022 - Springer
Background The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has
been the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) …
been the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma
J Peixoto, C Príncipe, A Pestana, H Osório… - International Journal of …, 2023 - mdpi.com
LRP1B remains one of the most altered genes in cancer, although its relevance in cancer
biology is still unclear. Recent advances in gene editing techniques, particularly …
biology is still unclear. Recent advances in gene editing techniques, particularly …
[HTML][HTML] Co-mutation of FAT3 and LRP1B in lung adenocarcinoma defines a unique subset correlated with the efficacy of immunotherapy
M Zhu, L Zhang, H Cui, Q Zhao, H Wang… - Frontiers in …, 2022 - frontiersin.org
Immunotherapy based on immune checkpoint inhibitors (ICIs) have demonstrated
remarkable survival benefits and gained regulatory approval in non-small cell lung cancer …
remarkable survival benefits and gained regulatory approval in non-small cell lung cancer …
[HTML][HTML] Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
Y Sato - Exploration of Targeted Anti-Tumor Therapy, 2022 - ncbi.nlm.nih.gov
Recently, technological advances in the detection and biological characterization of
circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into …
circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into …
Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
M Shin, S Ahn, J Jung, S Hyung, KM Kim… - Cancer …, 2023 - Wiley Online Library
Background Programmed death‐ligand 1 (PD‐L1) is an important screening biomarker to
select patients with gastric cancer (GC) for optimized treatment, including immune …
select patients with gastric cancer (GC) for optimized treatment, including immune …
[HTML][HTML] PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like …
YM Zhong, K Yin, Y Chen, Z Xie, ZY Lv… - Frontiers in …, 2022 - frontiersin.org
Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein–Barr virus
(EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint …
(EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint …
Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the …
Z Zhen, Z Shen, P Sun - Bioengineered, 2022 - Taylor & Francis
Hepatocellular carcinoma (HCC) has a high recurrence rate and mortality rate even after
surgery. Low-density lipoprotein receptor-related protein 1B (LRP1B) has proven to be …
surgery. Low-density lipoprotein receptor-related protein 1B (LRP1B) has proven to be …
Prognostic biomarkers correlated with immune infiltration in non‐small cell lung cancer
F Xu, W Cui, C Liu, F Feng, R Liu, J Zhang… - FEBS Open …, 2023 - Wiley Online Library
Lung cancer is the leading cause of cancer‐related mortality in men and women globally.
Non‐small cell lung cancer (NSCLC) is the most prevalent subtype, accounting for 85–90 …
Non‐small cell lung cancer (NSCLC) is the most prevalent subtype, accounting for 85–90 …
[HTML][HTML] Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker …
X Han, X Tang, H Zhu, D Zhu, X Zhang… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Objective Robust biomarker predicting efficacy of immunotherapy is limited. Circulating
tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease …
tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease …
[HTML][HTML] A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma
J Peng, D Zou, X Zhang, H Ma, L Han, B Yao - Journal of Translational …, 2024 - Springer
Background Identifying precise biomarkers of immunotherapy response for non-small cell
lung carcinoma (NSCLC) before treatment is challenging. This study aimed to construct and …
lung carcinoma (NSCLC) before treatment is challenging. This study aimed to construct and …